LAWRENCE, Mass., Dec. 11, 2017 /CNW/ -- NxStage Medical, Inc.
(Nasdaq: NXTM), a leading medical technology company focused
on advancing renal care, celebrates the achievement of over five
thousand patients having received a kidney transplantation after
performing more frequent home hemodialysis with NxStageⓇ
System OneTM.
"The more I realize how things have changed for the better, the
more amazed I am," said Maria
Jimenez, a former NxStage patient. "Switching from in-center
to home hemodialysis with NxStage System One was life-changing for
me. Soon after I started dialyzing more often at home, I noticed I
felt better and had more energy. I am extremely thankful for
everything home hemodialysis has given me, and I know more frequent
treatments got me where I am today. I performed more frequent home
hemodialysis with System One for four years before my transplant in
October and I feel as though I have a new lease on life. I am proud
to join 5,000 other NxStage patients having received a transplant.
I owe a lot to NxStage."
Kidney transplantation is often referred to as the gold standard
in dialysis care, but with waitlists for kidney transplants
increasing, the median wait time in the US is roughly 3.6
years.1 Patients on more frequent home hemodialysis with
the NxStage System One have a 14% higher incidence of receiving a
kidney transplant.2 More frequent home hemodialysis is
associated with: 13% lower risk of death compared to traditional
in-center hemodialysis3, 11% reduction in left
ventricular hypertrophy, reducing stress on the
heart4,5, and an 87% improvement in recovery time after
treatment.6
"Our hope for all kidney patients is to see each of them receive
the best treatment option for their specific needs. For many, that
means a kidney transplant." said Jeff
Burbank, Founder and CEO of NxStage Medical, Inc. "It's an
incredibly rewarding moment for NxStage to celebrate with over
5,000 of our former patients and know that for many of them, more
frequent home therapy with NxStage helped in their journey to
transplantation. It is moments like this that remind us of the
impact we are making on patients' lives."
The NxStage System One is the first and only truly portable
hemodialysis system cleared in the United States for home
hemodialysis during the day, with or without a care partner, or,
overnight as the patient and their care partner sleep. Its simple
and patient-focused design provides a range of hemodialysis therapy
options including more frequent treatments.
For more information on NxStage or the System One, visit:
http://www.nxstage.com.
The NxStage System One is a prescription device and, like all
medical devices, involves some risks. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream, and blood
loss due to clotting or accidental disconnection of the blood
tubing set. Certain risks are unique to the home. Treatments at
home are done without the presence of medical personnel and on-site
technical support. Patients and their partners must be trained on
what to do and how to get medical or technical help if needed.
Patients should consult with their doctor to understand the risks
and responsibilities of home and/or more frequent hemodialysis
using the NxStage System One. Additionally, the reported benefits
of home and/or more frequent hemodialysis may not be experienced by
all patients.
About the NxStage System One
The NxStage System One is
the first and only truly portable hemodialysis system cleared
specifically by the FDA for home hemodialysis and home
nocturnal hemodialysis. The simplicity and revolutionary size (just
over a foot tall) are intended to allow convenient use in patients'
homes and give patients the freedom to travel with their therapy.
When combined with the NxStage PureFlow™ SL Dialysis Preparation
System, patients are able to further simplify, using ordinary tap
water to create dialysis fluid on-site on-demand. Unlike
conventional hemodialysis systems, the System One family of
products requires no special infrastructure to operate. Under the
guidance of their physician, patients can use the NxStage System
One, with their trained partners, where, how and when it best meets
their needs, including while they are sleeping - at home or on
vacation and at a medically appropriate treatment frequency. In
addition, NxStage's Nx2me Connected Health® platform collects
important NxStage System One and patient information for flexible
viewing, monitoring and reporting that may improve patient
management and patient retention, as well as simplify alternative
site care. The System One is also used to provide a range of
flexible therapy options in more traditional care settings such as
hospitals, dialysis centers and skilled nursing facilities. Its
safety and performance have been demonstrated by experience with
more than 14 million treatments with over 30 thousand patients
around the world. www.nxstage.com.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical
technology company, headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
ESRD and acute kidney failure. NxStage also has established a small
number of dialysis clinics committed to the development of
innovative care delivery models for patients with ESRD. For more
information on NxStage and its products and services, please visit
the Company's websites at www.nxstage.com and
www.nxstagekidneycare.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this release that are not clearly
historical in nature are forward-looking, and the words
"anticipate," "believe," "expect," "estimate," "plan," and similar
expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors including those that are discussed in
NxStage's filings with the Securities and Exchange Commission,
including its Quarterly Report on Form 10-Q for the quarter ended
September 30, 2017. NxStage is under
no obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Media contact:
Kristen
K. Sheppard, Esq.
ksheppard@nxstage.com
References:
1. United States Renal Data System. 2015 Annual Data Report.
Accessed on, May 26, 2017.
https://www.usrds.org/2015/view/v2_07.aspx.
2. Weinhandl E, Liu J, Gilbertson D, Arneson T, Collins A.
Transplant incidence in frequent hemodialysis and matched
thrice-weekly hemodialysis patients. Poster presented at National
Kidney Foundation Spring Clinical Meeting, 2012.
3. Weinhandl ED, Lie J, Gilbertson DT, Arneson TJ, Collins AJ.
Survival in daily home hemodialysis and matched thrice-weekly
in-center hemodialysis patients. J Am Soc Nephrol.
2012;33(5):895-904.
4. FHN Trial Group. In-center hemodialysis six times per week
versus three times per week. N Engl J Med.
2010;363(24):2287-2300.
5. Culleton BF, Pannier B, Guerin AP, et al. Alterations of left
ventricular hypertrophy in and survival of patients receiving
hemodialysis: follow-up of an interventional study. J Am Soc
Nephrol. 2001;12(12):2759-2767.
6. Jaber BL, Lee Y, Collins AJ, et al. Effect of daily hemodialysis
on depressive symptoms and post dialysis recover time: interim
report from the FREEDOM (Following Rehabilitation, Economics and
Everyday-Dialysis Outcome Measurements) Study. Am J Kidney Dis.
2010;56(3):531-539.
View original content with
multimedia:http://www.prnewswire.com/news-releases/nxstage-celebrates-over-5000-home-hemodialysis-patients-receiving-kidney-transplants-300569028.html
SOURCE NxStage Medical, Inc.